TScan Therapeutics Inc
TCRX1.790USD
+0.070+4.07%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
101.58MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über TScan Therapeutics Inc Unternehmen
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Unternehmensinformationen
BörsenkürzelTCRX
Name des UnternehmensTScan Therapeutics Inc
IPO-datumJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Anzahl der mitarbeiter194
WertpapierartOrdinary Share
GeschäftsjahresendeJul 16
Addresse830 Winter Street
StadtWALTHAM
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02451
Telefon18573999500
Websitehttps://www.tscan.com
BörsenkürzelTCRX
IPO-datumJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2023
FY2022
FY2021
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.17M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Baker Bros. Advisors LP
5.31%
The Vanguard Group, Inc.
4.10%
Andere
58.80%
Aktionäre
Aktionäre
Anteil
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Baker Bros. Advisors LP
5.31%
The Vanguard Group, Inc.
4.10%
Andere
58.80%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
27.58%
Hedge Fund
21.45%
Venture Capital
19.23%
Investment Advisor/Hedge Fund
7.33%
Research Firm
3.61%
Individual Investor
0.39%
Bank and Trust
0.27%
Andere
20.13%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
192
48.33M
92.38%
-952.90K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
BlackRock Financial Management, Inc.
1.84M
3.53%
-21.35K
-1.14%
Mar 31, 2025
Bessemer Venture Partners
1.25M
2.38%
--
--
Mar 31, 2025
Alphabet, Inc.
1.08M
2.06%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
